Literature DB >> 30593719

Novel BEST1 mutations and special clinical characteristics of autosomal recessive bestrophinopathy in Chinese patients.

Jingyi Luo1, Mingkai Lin1, Xinxing Guo2, Xueshan Xiao1, Jiali Li1, Huan Hu1, Hui Xiao1, Xiaoyu Xu1, Yimin Zhong1, Shixian Long1, Guangwei Luo1, Lan Mi1, Xiangxi Chen1, Lei Fang1, Wei Wei1, Qingjiong Zhang1, Xing Liu1.   

Abstract

PURPOSE: The aim of this study was to describe the genetic and clinical characteristics of Chinese patients with autosomal recessive bestrophinopathy (ARB).
METHODS: This study presents a retrospective observational case series. Twenty-one ARB patients and 25 clinically healthy family members were recruited. The coding regions and adjacent intronic regions of BEST1 were analysed via Sanger sequencing. Clinical examinations, including ultrasound biomicroscopy, A-scan, optical coherence tomography, fundus autofluorescence, fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA) and visual electrophysiology, were reviewed.
RESULTS: Six novel mutations (c.380C>T, p.T127M; c.397A>G, p.N133D; c.500A>G, p.E167G; c.817G>A, p.V273M; c.174_176del, p.Q58del; and c.950_955del, p.S318_L319) and 8 previously reported mutations were identified. The p.R255W mutation had the highest frequency in our cohort. Twenty patients had serous retinal detachment with multifocal subretinal vitelliform deposits in the posterior poles. One patient exhibited chorioretinal atrophy. FFA revealed peripheral vascular leakage in 10 patients, and ICGA revealed hyperfluorescent spots in 8 patients. Visual electrophysiology was abnormal in all patients. Fifteen patients with angle closure (AC) or angle-closure glaucoma (ACG) had shallower anterior chambers and shorter axial lengths than the patients with open angle, contributing to their risk of developing AC/ACG. One patient developed AC during the 7-year follow-up period. The misdiagnosis and missed rates were 35.3% and 58.8%, respectively.
CONCLUSION: The six novel mutations and high frequency of p.R255W suggest ethnical differences in the BEST1 mutation spectrum among Chinese patients. BEST1 gene screening and detailed clinical examinations help establishing a diagnosis of ARB. Clinical evaluations of the risk of developing AC/ACG are recommended for ARB patients.
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BEST1 gene; angle-closure glaucoma; genotype-phenotype correlation; inherited retinal disease

Mesh:

Substances:

Year:  2018        PMID: 30593719     DOI: 10.1111/aos.13994

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  4 in total

1.  Branch retina vein occlusion combined with angle-closure glaucoma is associated with a mutation in BEST1: a case report.

Authors:  Xue Yin; Qinhua Cai
Journal:  BMC Ophthalmol       Date:  2022-06-29       Impact factor: 2.086

2.  Autosomal Recessive Bestrophinopathy: Clinical and Genetic Characteristics of Twenty-Four Cases.

Authors:  Hassan Khojasteh; Mohsen Azarmina; Nazanin Ebrahimiadib; Narsis Daftarian; Hamid Riazi-Esfahani; Houra Naraghi; Hamideh Sabbaghi; Alireza Khodabande; Hooshang Faghihi; Afrooz Moghaddasi; Fatemeh Bazvand; Masoud Reza Manaviat; Hamid Ahmadieh; Narges Hassanpoor; Fatemeh Suri
Journal:  J Ophthalmol       Date:  2021-04-30       Impact factor: 1.909

3.  Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy (ARB).

Authors:  Imen Habibi; Yosra Falfoul; Margarita G Todorova; Stefan Wyrsch; Veronika Vaclavik; Maria Helfenstein; Ahmed Turki; Khaled El Matri; Leila El Matri; Daniel F Schorderet
Journal:  Genes (Basel)       Date:  2019-11-21       Impact factor: 4.096

4.  Clinical Heterogeneity in Autosomal Recessive Bestrophinopathy with Biallelic Mutations in the BEST1 Gene.

Authors:  Karsten Hufendiek; Katerina Hufendiek; Herbert Jägle; Heidi Stöhr; Marius Book; Georg Spital; Günay Rustambayova; Carsten Framme; Bernhard H F Weber; Agnes B Renner; Ulrich Kellner
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.